Once Disparaged, ‘Me-Too’ Drugs Crucial For Lower Costs Of Cholesterol, Hepatitis C And Cancer Drugs

(By – John LaMattina, Forbes Contributor)

While the high cost of new drugs is worrisome, those responsible for drug benefit plans in the U.S. are especially concerned. When a cure for a hepatitis C drug, Sovaldi, was launched by Gilead at a cost of $84,000 for a 12-week cost of therapy, payers were outraged. Typical was last year’s comment by Ms. Karen Ignagni, the President of America’s Health Insurance Plans, the insurance industry’s trade association: Read more…

 

Notice: The “Read more…” link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.